.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The BOLD phase 2 study provided early dose-finding evidence for siponimod, an oral selective sphingosine-1-phosphate receptor modulator. Adults with relapsing-remitting multiple sclerosis were randomized to several siponimod doses or placebo and followed with serial MRI assessments. Siponimod produced a dose-dependent reduction in inflammatory MRI activity, helping identify the dose later used in phase 3 development. The study also established short-term tolerability and provided pharmacodynamic evidence that selective S1P modulation could meaningfully suppress disease activity. Although phase 2 MRI outcomes cannot substitute for long-term disability data, the trial was important in establishing a development pathway that ultimately led to the EXPAND trial in secondary progressive MS. For HCPs, the practical lesson is that MRI activity can be useful in early treatment evaluation, but treatment decisions should not rely on imaging alone. Clinical relapses, disability progression and safety monitoring remain central. Siponimod also requires CYP2C9 genotype-informed dosing and attention to infection, cardiac and ophthalmic risks. The study is relevant to IANCON's broad MS and disease-modifying therapy focus.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
The BOLD phase 2 study provided early dose-finding evidence for siponimod, an oral selective sphingosine-1-phosphate receptor modulator. Adults with relapsing-remitting multiple sclerosis were randomized to several siponimod doses or placebo and followed with serial MRI assessments. Siponimod produced a dose-dependent reduction in inflammatory MRI activity, helping identify the dose later used in phase 3 development. The study also established short-term tolerability and provided pharmacodynamic evidence that selective S1P modulation could meaningfully suppress disease activity. Although phase 2 MRI outcomes cannot substitute for long-term disability data, the trial was important in establishing a development pathway that ultimately led to the EXPAND trial in secondary progressive MS. For HCPs, the practical lesson is that MRI activity can be useful in early treatment evaluation, but treatment decisions should not rely on imaging alone. Clinical relapses, disability progression and safety monitoring remain central. Siponimod also requires CYP2C9 genotype-informed dosing and attention to infection, cardiac and ophthalmic risks. The study is relevant to IANCON's broad MS and disease-modifying therapy focus.
4 weeks back
A bioengineered oral nanozyme microsupplement converts pathological ROS into a protective polydopamine hydrogel shield. By curbing neutrophil extracellular traps and balancing T cells, this platform outperforms standard 5-ASA in preclinical colitis models, opening new paths for sustained remission.
Yesterday
Recent research reveals that downregulating YAP1/TAZ-TEAD via Hippo signaling triggers spontaneous human trophoblast syncytialization in 3D cultures, illuminating placental biology and preeclampsia.
3 weeks back
Abdominal aortic aneurysm rupture remains a catastrophic vascular emergency. Groundbreaking research reveals that USP53 accelerates aneurysm progression by reprogramming smooth muscle cell metabolism toward aerobic glycolysis, highlighting a promising target beyond conventional diameter-based surveillance.
2 days back
A breakthrough study leverages natural language processing to accurately identify incident medication-related osteonecrosis of the jaw and track antiresorptive drug holidays from clinical narratives in electronic health records, advancing osteoporosis pharmacovigilance and dental safety.
2 days back
Recent research defines ferro-aging as a conserved iron-lipid axis driving organ decline across primates. Age-related iron dyshomeostasis stimulates ACSL4-mediated lipid peroxidation, promoting cellular senescence. Notably, vitamin C directly inhibits ACSL4, suppressing phospholipid oxidation and multi-organ decay.
3 days back
